Furiex Pharmaceuticals, Inc. (FURX) Announces Acceptance To Late-Breaking Abstract Session At Digestive Disease Week 2014
4/4/2014 7:06:50 AM
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced that results from its two Phase III clinical trials of eluxadoline in patients with diarrhea-predominant irritable bowel syndrome will be presented in a Late-Breaking Abstract Session at Digestive Disease Week (DDW) 2014, to be held May 3-6 at McCormick Place in Chicago, IL.
Help employers find you! Check out all the jobs and post your resume.
comments powered by